INTRODUCTION
The over treatment of early stage prostate cancer (PCa) has prompted significant changes in recommendations for treatment. 1 Current guidelines suggest delaying therapy with curative intent for patients deemed "very low" and "low" risk, as defined by the National Comprehensive Cancer Network. 2 This management strategy, referred to as active surveillance (AS), may confer adequate and comparable oncologic outcomes to definitive therapy. 3 Therefore, it is important to consider health-related quality-of-life (HRQoL) outcomes when deciding on an approach to minimize both the physical and psychological burden of the disease and its treatment. 4 To help patients weigh the costs and benefits of PCa management strategies, studies that examine the impact of treatment choice on short-term and long-term HRQoL are warranted. Patients who are managed with AS may be spared some of the decline in physical HRQoL compared with patients who receive definitive treatments, such as radical prostatectomy (RP), but they could concomitantly suffer greater mental health declines because of the anxiety of delaying therapy. 5 Although prior studies have examined HRQoL outcomes after definitive treatments for PCa, [6] [7] [8] few have focused on patients managed on AS or have compared patients who delay therapy with those who select definitive therapy. 9, 10 For the current study, we assessed the impact of PCa management strategy on disease-specific and general HRQoL outcomes over time in a prospective, racially diverse, and contemporary cohort of men with low-risk PCa who were counseled at multidisciplinary clinics. Patients who elected to undergo RP were compared with those who were managed with AS over a 3-year period.
MATERIALS AND METHODS

Study Population
All patients were enrolled in the Center for Prostate Disease Research (CPDR) Multicenter National Database, which contains demographic, clinical, treatment, and outcomes data. Informed consent was obtained at the time of transrectal ultrasound-guided biopsy for suspicion of PCa, as described previously. 11 Prospective collection of HRQoL data was institutional review board (IRB)-approved and initiated in 2007. Sites included Madigan Army Medical Center (Tacoma, Wash), Naval Medical Center (San Diego, Calif), Virginia Mason (Seattle, Wash), and Walter Reed National Military Medical Center (Bethesda, Md). Site participation in the CPDR database was granted by each institutional IRB, with second-tier IRB approval by the Uniformed Services University of the Health Sciences (Bethesda, Md).
Survey Instruments
HRQoL data were captured using 2 validated questionnaires: the Expanded Prostate Cancer Index Composite (EPIC) and the 36-item RAND Medical Outcomes Study Short Form (SF-36) survey. [12] [13] [14] The EPIC measures paired subscales that evaluate function and bother for urinary, sexual, bowel, and hormone domains, and higher scores indicate better HRQoL (score range, 0-100). The SF-36 survey measures 8 subscales that combine into Physical Component Summary (PCS) and Mental Component Summary (MCS) scores. Surveys were administered immediately before or after biopsy (baseline) and at 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, and 36 months.
Eligibility criteria included biopsy-confirmed PCa diagnosed at age 75 years, completion of the baseline survey and at least 1 follow-up survey, and patient followup for a minimum of 12 months (Fig. 1) . The study sample was restricted to patients who were diagnosed with "low-risk" PCa, defined as a clinical T1 to T2a tumor, a biopsy Gleason score 6, and a prostate-specific antigen (PSA) level <10 ng/mL. 15 Comorbidity included a count of up to 8 conditions: lung disease, heart disease, hypertension, cerebral vascular accident, diabetes, elevated cholesterol, prostatitis, and renal insufficiency.
Patients who underwent RP within 6 months of diagnosis were compared with those who were managed with AS. Patients in the AS cohort received no definitive treatment within 1 year of diagnosis and had either AS noted as the management strategy in their medical record or at least 1 PSA level or repeat biopsy within 18 months. Treatments received subsequent to meeting these definitions were considered secondary.
Statistical Analysis
Demographics, clinical characteristics, and baseline HRQoL scores were compared between treatment cohorts using Welch t tests for continuous variables, chi-square tests for categorical variables, and Cochran-Armitage tests for ordinal variables. For the primary study objective of comparing differences between treatment groups over time, mean scores were estimated using generalized estimating equations (GEE), with autoregressive working correlation and sandwich variance estimators. 16 Time point was included as a categorical covariate. Other covariates included treatment, time-by-treatment interactions, mean-centered baseline age and HRQoL, race/ethnicity, and number of comorbidities (0, 1, 2). Adjusted mean scores per treatment group and time point were estimated for patients of mean age and baseline HRQoL at the reference level of the other covariates.
The secondary study objective was to examine the absolute change from baseline for each treatment group using GEE models with change from baseline score as the outcome variable. To distinguish clinically meaningful differences from statistically significant differences, in the absence of an anchor-based evaluation for each subscale score, the minimum clinically important difference (MCID) was calculated as 0.5 baseline score standard deviations for each cohort. Equivalence was demonstrated when the entire 95% confidence interval for the adjusted mean difference or change was within the range from 2MCID to 1 MCID. 17 Patients were censored at the date of secondary treatment, if any. Patients in the RP cohort who had not yet undergone RP before completing their 3-month and 6-month surveys were excluded from analyses of those time points. Two sensitivity analyses were conducted: 1 included all surveys from patients who received secondary treatment, and 1 had missing follow-up scores imputed using multiple imputations. All statistical tests were 2-sided, and P values were adjusted for multiple time points using the Bonferroni method. Analyses were conducted using SAS statistical software (version 9.3; SAS Institute Inc., Cary, NC).
RESULTS
Of the 745 patients who met initial eligibility criteria, 389 (52%) had low-risk PCa. Among those, 228 (59%) underwent RP, and 77 (20%) were managed with AS ( Fig. 1) . The remaining 84 patients selected other primary treatment modalities and were excluded.
The mean age at diagnosis was 58 years and 65 years for patients who underwent RP and AS, respectively (P < .0001) ( Table 1 ). On average, 2.8 months elapsed between diagnosis and RP. There were differences in site of enrollment and months of follow-up (P 5 .0001). At baseline, the AS cohort reported lower sexual function and bother scores (P 5 .002 and P 5 .03, respectively) ( Table 2) . No other statistically significant differences in baseline HRQoL scores were observed. Survey completion patterns were examined over time (Supporting Table 1 ; see online supporting information). At 36 months, the survey completion rate remained high for the AS and RP cohorts at 72% and 60%, respectively. On average, patients in both treatment groups completed 5 HRQoL surveys. Eleven patients in each group were censored on the date of secondary treatment, including 5 AS patients who went on to undergo RP.
HRQoL Associated With Sexual Symptoms
Adjusted mean sexual function and bother scores were lower for RP patients at all follow-up time points ( Fig.  2A,B) . In the RP cohort, sexual function and bother scores improved after 6 months, stabilized by 2 years, but remained significantly lower than those for AS patients at 3 years (P 5 .01 and P 5 .049, respectively) ( Table 3) .
HRQoL Associated With Urinary Symptoms
Compared with the AS cohort, men in the RP cohort reported significantly poorer urinary function at all follow-up time points (Fig. 2C) . Urinary function scores recovered between 3 months and 12 months in the RP cohort but remained lower than in the AS cohort at 3 years (P 5 .046) ( Table 3) . Urinary bother scores were significantly lower in the RP cohort at 3 months, 6 months, and 12 months (Fig. 2D) . RP cohort urinary bother scores recovered by 18 months and were equivalent to AS scores at 2 years and 3 years (Table 3) .
HRQoL Associated With Bowel and Hormone Symptoms
Patients in the RP cohort reported worse bowel function at 3 months than patients in the AS cohort. No other statistically significant differences in bowel function or bother were observed between cohorts; bowel function was equivalent at 2 years, and bother was equivalent at 1 year and 2 years (Fig. 2E,F , Table 3 ). In addition, no statistically significant differences in hormone function or bother were observed between cohorts at any time point (Fig. 2G ,H, Table 3 ).
General HRQoL
RP patients exhibited significantly lower SF-36 PCS scores at 3 months compared with AS patients (Fig. 2I) . Of the 4 subscales that constitute the PCS, the RP cohort had significantly lower mean scores in physical functioning at 3 months and role-physical at 3 months and 6 months (Supporting Fig. 2A,B ; see online supporting information). After 6 months, no significant differences in PCS or individual physical health subscale scores were observed, and PCS scores were equivalent at 1 year and 2 years (Table 3) .
No significant differences in MCS scores were observed between cohorts at any time point (Fig. 2J , Table 3), and MCS scores were equivalent at 1 year. Of the 4 subscales that constitute the MCS, the RP cohort displayed significantly lower mean scores in social functioning at 3 months and 6 months. No other differences in mental health subscale scores were observed (Supporting Fig. 2 ; see online supporting information).
When the analyses were repeated to include the patients who received secondary treatment (Supporting Table 2 ; see online supporting information) or missing data using imputation (Supporting Table 3 ; see online supporting information), similar findings were observed. Sexual and urinary function scores remained significantly lower in the RP cohort at 2 years and 3 years, and sexual bother scores remained significantly lower at 1 year. Other differences between cohorts did not retain statistical significance, but the magnitude of the adjusted mean differences was comparable for all time points and subscales.
Change in HRQoL From Baseline Table 4 provides adjusted mean absolute change scores from baseline to 1 year, 2 years, and 3 years after diagnosis Mean scores from the multivariable model were fitted with generalized estimating equations and were adjusted for age, race/ethnicity, comorbidities, and baseline health-related quality-of-life scores. For these charts, mean scores were calculated for a patient of average age with an average baseline score who was at the reference level for the other covariates (Caucasian race, 2 comorbidities). Bars represent 95% confidence intervals, and asterisks indicate statistical significance after adjustment for the number of time points (n 5 7) using Bonferroni correction (a single asterisk indicates P <.05; double asterisks, P <.01; triple asterisks, P <.001). Solid lines indicate data from the AS cohort, and dashed lines indicate data from the RP cohort.
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Cancer July 15, 2015 for each subscale and cohort. In the AS cohort, there were no statistically significant or clinically meaningful declines in HRQoL. The only statistically significant change from baseline in the AS cohort was a decline in the SF-36 PCS score at 3 years (23; 95% confidence interval, 25, 21), but this decline was not greater than the MCID. In contrast, the RP cohort experienced clinically meaningful and statistically significant declines in sexual function, sexual bother, and urinary function scores that persisted for 3 years.
DISCUSSION
In the United States, the use of AS for low-risk PCa rose from 9.7% in 2004 to 15.3% in 2007 according to Surveillance, Epidemiology, and End Results and Medicare data. 18 A recent nationwide survey revealed that surveillance strategies are accepted by clinicians but are largely underused, and only 22.1% of urologists and radiooncologists would currently recommend AS for low-risk PCa. 19 The relative paucity of prospective data on longterm follow-up of HRQoL outcomes in PCa cohorts makes the decision regarding treatment choice even more difficult for patients. To better understand the consequences of choosing AS, in this study, we assessed HRQoL changes across time in patients with low-risk PCa who were managed with either AS or RP. It is noteworthy that patients in the AS cohort were spared the declines in urinary and sexual function experienced by those in the RP cohort without suffering concomitant declines in mental HRQoL.
Although several studies have examined the effects of different PCa treatment modalities on HRQoL outcomes, few have prospectively compared RP versus AS or watchful waiting (WW). 20, 21 A randomized clinical trial of patients who either underwent RP or received WW indicated that the prevalence of erectile dysfunction and urinary incontinence was higher in the RP cohort. 21 In another prospective study, patients who underwent RP had worse urinary and erectile function and urinary continence than those who were managed with WW after 1 year. 22 A recent Cancer of the Prostate Strategic Urologic Research Endeavor study compared longitudinal HRQoL among various treatment modalities and a combined AS/ WW group and observed that surgery had the largest impact on sexual function and bother and urinary function. 23 The current study confirms that these conclusions hold when examined in a low-risk cohort of RP versus strictly AS patients.
Our finding that men who undergo RP and AS exhibit comparable mental health outcomes is consistent with prior population-based studies, which demonstrated no significant changes in MCS scores between AS and RP cohorts at 3 years 24 or between RP and WW cohorts at 5 to 10 years, 25 and a randomized trial, which demonstrated no difference in the prevalence of anxiety or depressed mood between RP and WW cohorts after 12 years. 10 In addition, we observed no significant change from baseline mental health for those who were managed on AS throughout the 3-year study period. This finding is supported by a previous study in which Finnish men on AS reported less general anxiety 18 months after diagnosis 26 and did not display loss of mental HRQoL after 1 year compared with the general population. 27 This is an important finding given concerns that patients who delay treatment may experience short-term or lasting reductions in mental health.
The current study is one of the first to report on longitudinal HRQoL in a carefully defined, prospective cohort of patients who underwent AS. A rigorous AS definition was implemented to help distinguish AS patients from those choosing WW. Moreover, all patients enrolled in this study attended a CPDR multidisciplinary clinic, which included radiation and medical oncologists, urologic surgeons, and nurse practitioners, to receive balanced and tailored counseling on their treatment options. This setting is an important study strength, because the multidisciplinary approach is being used increasingly at medical centers that provide treatment for PCa. 28 In our study, 14% of AS patients and 5% of RP patients went on to receive secondary treatment after a mean of 24 months and 16 months, respectively. The exclusion of these patients does not appear to have biased our results; when the analyses were repeated without censoring, the overall study conclusions were unaltered. Future studies should examine the HRQoL of patients who receive secondary treatment after initial AS, because they may experience worse post-treatment HRQoL than those who undergo definitive treatment immediately.
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Other study strengths include the racial diversity of the cohort, use of validated HRQoL metrics, and adjustment of follow-up data for baseline scores and clinical characteristics. In addition, MCIDs were presented for each subscale, allowing for a practical interpretation of observed differences in scores. HRQoL score differences can be difficult to interpret, because statistically significant differences are not always clinically meaningful. 30 Consideration of MCIDs is therefore paramount for HRQoL results to be interpretable for both clinicians and patients. Because patients in our study were self-selected and were not randomized into treatment groups, it is possible that the patients who elected AS may have been less anxious than those who chose to undergo immediate curative therapy. However, no significant differences were observed in mental health scores between the RP and AS cohorts at baseline. Randomized controlled trials like the ProtecT (Prostate Testing for Cancer and Treatment) trial 31 will be able to test whether the study conclusions hold in the absence of any selection biases, but such studies are considered unfeasible in the United States. This prospective cohort design is the most rigorous design possible.
Another limitation of the study was the small sample size of the AS cohort, particularly at the later time points. Declines in sample size were because of administrative censoring, conversion to secondary treatment, and missing data. Despite the sample size and conservative adjustment for multiple comparisons, several statistically significant differences persisted at the 3-year follow-up assessment. To assess the effect of missing data, missing HRQoL scores for patients who had sufficient follow-up were imputed in a separate sensitivity analysis. This analysis yielded similar results, suggesting that missing data did not meaningfully influence the results. However, missing data still could have introduced bias, and future studies will be needed to confirm our findings.
In this study, it was not possible to address erectile aid use or other lifestyle changes that may impact HRQoL. 32 However, the use of such aids is widespread in the United States and is unlikely to differ between patients choosing AS versus RP. 33 The generalizability of our findings may also be limited given our strict eligibility criteria and unique cohort features. For instance, our results may not apply to all health care systems, because patients were enrolled at US medical facilities, and the majority of patients were military health care beneficiaries. However, the multi-institutional and contemporary nature of our cohort overcomes several of these limitations compared with single-institution reports and historic WW series. Ultimately, patient preference remains a central consideration in treatment decision making, and the findings from this study can help inform and direct that choice.
Conclusions
In this study, we observed no differences in mental health outcomes but worse urinary and sexual HRQoL for up to 3 years in patients who underwent surgery for low-risk PCa compared with those who underwent AS. The current data offer support for the management of patients with low-risk PCa using AS as a means of postponing the morbidity associated with RP without concomitant mental health declines.
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